{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:22:46Z","timestamp":1785190966906,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Innovation Project of Guangxi Graduate Education","award":["YCBZ2022079"],"award-info":[{"award-number":["YCBZ2022079"]}]},{"name":"Self-financing Project of Health Commission of Guangxi Zhuang Autonomous Region","award":["Z20200398"],"award-info":[{"award-number":["Z20200398"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"DOI":"10.1007\/s00384-023-04378-w","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T11:03:23Z","timestamp":1679915003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparative efficacy and safety of combination therapy with infliximab for Crohn\u2019s disease: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-6693","authenticated-orcid":false,"given":"Bing","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6610-4310","authenticated-orcid":false,"given":"Daiyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1877-4285","authenticated-orcid":false,"given":"Xiaodan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3744-2737","authenticated-orcid":false,"given":"Shiquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7292-7484","authenticated-orcid":false,"given":"Junhua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7986-1740","authenticated-orcid":false,"given":"Xiaofang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-936X","authenticated-orcid":false,"given":"Jiatong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-7124","authenticated-orcid":false,"given":"Shang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-5160","authenticated-orcid":false,"given":"Weizheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2663-0652","authenticated-orcid":false,"given":"Ziqian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-1622","authenticated-orcid":false,"given":"Lingling","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7144-9508","authenticated-orcid":false,"given":"Xiaoping","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"4378_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","volume":"11","author":"P Gionchetti","year":"2017","unstructured":"Gionchetti P, Dignass A, Danese S, Magro F, Rogler G, Lakatos PL et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: Part 2: Surgical management and special situations. J Crohns Colitis 11:135\u2013149. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw169","journal-title":"J Crohns Colitis"},{"key":"4378_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"S Hanauer","year":"2002","unstructured":"Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colomber JF et al (2002) Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 359:1541\u20131549. https:\/\/doi.org\/10.1016\/S0140-6736(02)08512-4","journal-title":"Lancet"},{"issue":"15","key":"4378_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. N Engl J Med 337(15):1029\u20131035. https:\/\/doi.org\/10.1056\/NEJM199710093371502","journal-title":"N Engl J Med"},{"issue":"9","key":"4378_CR4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN et al (2004) Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med 350(9):876\u2013885. https:\/\/doi.org\/10.1056\/NEJMoa030815","journal-title":"N Engl J Med"},{"key":"4378_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/apt.13835","volume":"45","author":"J Kirchgesner","year":"2017","unstructured":"Kirchgesner J, Lemaitre M, Rudnichi A, Racine A, Zureik M, Carbonnel F et al (2017) Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009\u20132014. Aliment Pharmacol Ther 45:37\u201349. https:\/\/doi.org\/10.1111\/apt.13835","journal-title":"Aliment Pharmacol Ther"},{"key":"4378_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","volume":"130","author":"M L\u00e9mann","year":"2006","unstructured":"L\u00e9mann M, Mary J, Duclos B, Veyrac M, Dupas J, Delchier JC et al (2006) Infliximab plus azathioprine for steroid-dependent Crohn\u2019s disease patients: a randomized placebo-controlled trial. Gastroenterology 130:1054\u20131061. https:\/\/doi.org\/10.1053\/j.gastro.2006.02.014","journal-title":"Gastroenterology"},{"key":"4378_CR7","doi-asserted-by":"publisher","unstructured":"D\u2019Haens G, Baert F, van AG, Caenepeel P, Vergauwe P, Tuynman H et al (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet\u00a0371:660\u2013667. https:\/\/doi.org\/10.1016\/S0140-6736(08)60304-9","DOI":"10.1016\/S0140-6736(08)60304-9"},{"key":"4378_CR8","doi-asserted-by":"publisher","unstructured":"Chande N, Townsend CM, Parker CE, MacDonald JK (2016) Azathioprine or 6-mercaptopurine for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 10:CD000545. https:\/\/doi.org\/10.1002\/14651858.CD000545.pub5","DOI":"10.1002\/14651858.CD000545.pub5"},{"key":"4378_CR9","doi-asserted-by":"publisher","unstructured":"McDonald JWD, Wang YJ, Tsoulis DJ, MacDonald JK, Feagan BG (2014) Methotrexate for induction of remission in refractory Crohn\u2019s disease. Cochrane Database Syst Rev CD003459. https:\/\/doi.org\/10.1002\/14651858.CD003459.pub4","DOI":"10.1002\/14651858.CD003459.pub4"},{"key":"4378_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"4378_CR11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","volume":"17","author":"JP Jansen","year":"2014","unstructured":"Jansen JP, Trikalinos T, Cappelleri JC, Daw J, Andes S, Eldessouki R et al (2014) Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 17:157\u2013173. https:\/\/doi.org\/10.1016\/j.jval.2014.01.004","journal-title":"Value Health"},{"key":"4378_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, Salanti G (2013) Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159:130\u2013137. https:\/\/doi.org\/10.7326\/0003-4819-159-2-201307160-00008","journal-title":"Ann Intern Med"},{"key":"4378_CR13","unstructured":"Higgins JPT GS, editors (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration"},{"key":"4378_CR14","unstructured":"Murad MH MV, Ioannidis JPA, Prasad K, Cook DJ, Guyatt G (2014) Advanced topics in systematic reviews: fixed-effects and random effects models. The JAMA Network Press 07\u2013514"},{"issue":"7414","key":"4378_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"key":"4378_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, Higgins JPT (2012) Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 3:111\u2013125. https:\/\/doi.org\/10.1002\/jrsm.1045","journal-title":"Res Synth Methods"},{"key":"4378_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163\u2013171. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.03.016","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"4378_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/00042737-200601000-00003","volume":"18","author":"O Schr\u00f6der","year":"2006","unstructured":"Schr\u00f6der O, Blumenstein I, Stein J (2006) Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn\u2019s disease: a controlled pilot study. Eur J Gastroenterol Hepatol 18(1):11\u201316. https:\/\/doi.org\/10.1097\/00042737-200601000-00003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"4378_CR19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","volume":"146","author":"B Feagan","year":"2014","unstructured":"Feagan B, McDonald J, Panaccione R, Enns RA, Bernstein CN, Ponich TP (2014) Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn\u2019s disease. Gastroenterology 146:681-688.e1. https:\/\/doi.org\/10.1053\/j.gastro.2013.11.024","journal-title":"Gastroenterology"},{"key":"4378_CR20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/apt.13139","volume":"41","author":"J Colombel","year":"2015","unstructured":"Colombel J, Reinisch W, Mantzaris G, Kornbluth A, Rutgeerts P, Tang K (2015) Randomised clinical trial: deep remission in biologic and immunomodulator na\u00efve patients with Crohn\u2019s disease\u2014a SONIC post hoc analysis. Aliment Pharmacol Ther 41:734\u2013746. https:\/\/doi.org\/10.1111\/apt.13139","journal-title":"Aliment Pharmacol Ther"},{"key":"4378_CR21","first-page":"75","volume":"18","author":"ZY Wang","year":"2014","unstructured":"Wang ZY, Zheng L, Zhang MH (2014) Effect observation of infliximab combined with azathioprine on treatment of patients with Crohn\u2019s disease. Clinic Med in Practice 18:75\u201378","journal-title":"Clinic Med in Practice"},{"key":"4378_CR22","first-page":"403","volume":"26","author":"L Chen","year":"2016","unstructured":"Chen L, Wen F, Yu WZ, Xia LL, Dan X (2016) Clinical curative effects of infliximab combined with azathioprine on Crohn\u2019s disease. Southwest National Defense Medicine 26:403\u2013406","journal-title":"Southwest National Defense Medicine"},{"key":"4378_CR23","first-page":"2919","volume":"33","author":"CM Fan","year":"2018","unstructured":"Fan CM, Chen FH (2018) Clinical study of thalidomide combined with infliximab in treatment of Crohn\u2019s disease. Drugs & Clinic 33:2919\u20132923","journal-title":"Drugs & Clinic"},{"key":"4378_CR24","first-page":"51","volume":"41","author":"YH Shi","year":"2020","unstructured":"Shi YH, Tang MC, Wang JS, Sun MM, Weng Y, Liu ZJ (2020) Enteral nutrition combined with infliximab in treatment of adult Crohn\u2019s disease: a randomized controlled trial. J Tongji University: Med Edition 41:51\u201356","journal-title":"J Tongji University: Med Edition"},{"key":"4378_CR25","first-page":"29","volume":"5","author":"SY Shen","year":"2020","unstructured":"Shen SY, Zhao WY, Feng JZ (2020) Clinical effect of thalidomide combined with infliximab in the treatment of patients with Crohn\u2019s disease. Clinic Med 5:29\u201331","journal-title":"Clinic Med"},{"key":"4378_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/ibd.20014","volume":"13","author":"B Sands","year":"2007","unstructured":"Sands B, Kozarek R, Spainhour J, Barish C, Becker S, Goldberg L et al (2007) Safety and tolerability of concurrent natalizumab treatment for patients with Crohn\u2019s disease not in remission while receiving infliximab. Inflamm Bowel Dis 13:2\u201311. https:\/\/doi.org\/10.1002\/ibd.20014","journal-title":"Inflamm Bowel Dis"},{"key":"4378_CR27","unstructured":"Zhou TX (2017) Clinical study on treatment of Crohn\u2019s disease treated with curcuma enema. [dissertation\/master\u2019s thesis]. [Nanjing (IL)]: Nanjing University of Chinese Medicine"},{"issue":"30","key":"4378_CR28","first-page":"133","volume":"24","author":"XS Yang","year":"2018","unstructured":"Yang XS (2018) Clinical efficacy of azathioprine combined with infliximab therapy for Crohn\u2019s disease. Contempo med 24(30):133\u2013134","journal-title":"Contempo med"},{"key":"4378_CR29","first-page":"1253","volume":"31","author":"YT Hu","year":"2018","unstructured":"Hu YT, Sun SH, Zhang J, Jia GC, Hou HT, Bai Y et al (2018) Infliximab in the treatment of inflammatory bowel disease: an analysis of 30 cases. Chinese J Clinic res 31:1253\u20131256","journal-title":"Chinese J Clinic res"},{"key":"4378_CR30","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","volume":"134","author":"G Van Assche","year":"2008","unstructured":"Van Assche G, Magdelaine-Beuzelin C, D\u2019Haens G, Baert F, Noman M, Vermeire S et al (2008) Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134:1861\u20131868. https:\/\/doi.org\/10.1053\/j.gastro.2008.03.004","journal-title":"Gastroenterology"},{"key":"4378_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027","volume":"30","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW et al (2009) Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 30:210\u2013226. https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04027","journal-title":"Aliment Pharmacol Ther"},{"issue":"19","key":"4378_CR32","first-page":"2973","volume":"35","author":"XY Tan","year":"2019","unstructured":"Tan XY, Song L, Jiang Z (2019) Meta-analysis of Infliximab combined with azathioprine and Infliximab combined with enteral nutrition in the treatment of Crohn\u2019s disease. Modern Medicine and Hygiene 35(19):2973\u20132977","journal-title":"Modern Medicine and Hygiene"},{"issue":"12","key":"4378_CR33","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","volume":"6","author":"S Singh","year":"2021","unstructured":"Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R et al (2021) Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 6(12):1002\u20131014. https:\/\/doi.org\/10.1016\/S2468-1253(21)00312-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4378_CR34","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/gut.2006.09997","volume":"56","author":"S Vermeire","year":"2007","unstructured":"Vermeire S, Noman M, Van Assche G, Baert F, D\u2019Haens G, Rutgeerts P (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease. Gut 56:1226\u20131231. https:\/\/doi.org\/10.1136\/gut.2006.09997","journal-title":"Gut"},{"key":"4378_CR35","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F et al (2017) Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 318:1679\u20131686. https:\/\/doi.org\/10.1001\/jama.2017.16071","journal-title":"JAMA"},{"key":"4378_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","volume":"9","author":"DS Kotlyar","year":"2011","unstructured":"Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M et al (2011) A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clinic Gastroenterol Hepatol 9:36\u201341. https:\/\/doi.org\/10.1016\/j.cgh.2010.09.016","journal-title":"Clinic Gastroenterol Hepatol"},{"key":"4378_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"JF Colombel","year":"2004","unstructured":"Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD et al (2004) The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo clinic experience in 500 patients. Gastroenterology 126:19\u201331. https:\/\/doi.org\/10.1053\/j.gastro.2003.10.047","journal-title":"Gastroenterology"},{"key":"4378_CR38","doi-asserted-by":"publisher","unstructured":"Vickers AD, Ainsworth C, Mody R, Bergman A, Ling CS, Medjedovic J et al (2016) Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis. PLoS One\u00a011:e0165435. https:\/\/doi.org\/10.1371\/journal.pone.0165435","DOI":"10.1371\/journal.pone.0165435"},{"key":"4378_CR39","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1177\/0272989X17711933","volume":"37","author":"C Cameron","year":"2017","unstructured":"Cameron C, Ewara E, Wilson FR, Varu A, Dyrda P, Hutton B et al (2017) The importance of considering differences in study design in network meta-analysis: an application using anti-tumor necrosis factor drugs for ulcerative colitis. Med Decis Making 37:894\u2013904. https:\/\/doi.org\/10.1177\/0272989X17711933","journal-title":"Med Decis Making"},{"issue":"10","key":"4378_CR40","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/apt.14030","volume":"45","author":"A Cholapranee","year":"2017","unstructured":"Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN (2017) Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther 45(10):1291\u20131302. https:\/\/doi.org\/10.1111\/apt.14030","journal-title":"Aliment Pharmacol Ther"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-023-04378-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-023-04378-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-023-04378-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T11:15:13Z","timestamp":1703157313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-023-04378-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4378"],"URL":"https:\/\/doi.org\/10.1007\/s00384-023-04378-w","relation":{},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"17 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"82"}}